Funding Portfolio
Biotech Acquisition/Equity Investments/In-licensing/
Let us present an overview of the entire portfolio for which we are proud to assist in funding:
These opportunities represent paradigm changes in healthcare and modernization of diagnostics. There are non-invasive to assess analytes in hematology and chemistry. For example, blood glucose can be accurately assessed without a drop of blood. Moving to another device company, this company is nicely progressed to manufacturing with a device which can provide diagnostic information by USB to cell phones. Your physician gets the ECHO or ECG results from the diagnostic equipment remotely to his cell phone, hence, immediately available for diagnosis and prompt, diagnostically appropriate care.
Our pipelines are saturated with the future of oncological care. They also include the latest business strategy of, medical foods, which many major pharmaceutical companies are pursuing to escape the dangers of the patent cliff of conventional drugs yet having an immediate revenue stream. If you have an interest in taking a look at BP/ES for companies who will be producing changing the landscape of healthcare for the future and need to know more, contact:
http://nwclinicalresearch.com/
jtaylor@nwclinicalresearch.com